Amneal Pharmaceuticals Inc. Class A (AMRX)
NASDAQ: AMRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AMRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.36B
- P/E (TTM)
- 52.80
- Forward P/E
- 17.13
- EPS (TTM)
- $0.40
- Dividend yield
- None
- 52-week range
- 11.71 – 22.13
- Day range
- 21.07 – 21.70
- Volume / Avg
- 1.67M / 3.16M
- Beta
- —
- Shares outstanding
- 348.41M
52-week range
AMRX stock today
Amneal Pharmaceuticals (AMRX) closed at $21.12 on Nov 20, down 1.26% (-$0.27), versus the S&P 500's 3.70% decline. At this level, AMRX sits near the top of its 52-week range of $11.71 to $22.13: 4.5% below the high, set on Nov 18, 2026 and 80.4% above the low. AMRX is up 67.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 76.7%.
At 52.8x trailing earnings, Amneal Pharmaceuticals trades above the peer-group median of 47.8x. Its forward P/E of 17.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Amneal Pharmaceuticals
Company profileAmneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Chirag K. Patel
- Headquarters
- Bridgewater, NJ
- Employees
- 8,700
- Website
- amneal.com
Financial highlights
Full financialsIn fiscal 2025, Amneal Pharmaceuticals generated $3.02 billion in revenue, up 8.0% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $72.1 million, for a net margin of 2.4% versus a median of -3.5% in the prior 5 years. Gross margin was 36.9% (up from 36.5%) and operating margin 13.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B |
| Growth | +8.05% | +16.73% | +8.20% | +5.67% | +5.08% |
| Net income | $72.06M | $-116.89M | $-83.99M | $-270.58M | $13.16M |
| EPS (diluted) | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$24.29+15.01%
- Strong buy 3
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $0.15 vs $0.23
- Surprise
- -34.78%
AMRX news
All AMRX news- Sanofi's Next-Generation Rabies Vaccine Secures Approval in EUNasdaqSNY, ADPT, ACIU, AMRX
- SNY Wins FDA Approval for Infilbray in Type 3 Gaucher DiseaseNasdaqSNY, ADPT, ACIU, AMRX
- GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung CancerNasdaqGSK, ADPT, ACIU, AMRX
- Amneal's Xolair Biosimilar Adcomfo Gets EU Marketing Authorization For Allergic ConditionsNasdaqALVO, AMRX, NVS, UHAL.B
- Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®GlobeNewswire
- Summit Stock Falls on FDA Rejection for Lung Cancer DrugNasdaqSMMT, ADPT, ACIU, AMRX
- Kodiak Q3 Loss Wider Than Expected, Pipeline Development in FocusNasdaqKOD, REGN, ACIU, AMRX
- Show Me The Money: After A 120% Rally, Amneal (AMRX) Positions For Its Next Growth Chapter In 2027NasdaqAMRX, BF.A
Amneal Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KNSAKiniksa Pharmaceuticals International plc Class A | 93.90 | +0.38% | $7.38B | vs AMRX |
| ALKSAlkermes plc | 44.94 | -2.69% | $7.55B | vs AMRX |
| RYTMRhythm Pharmaceuticals Inc. | 112.36 | -3.80% | $7.79B | vs AMRX |
| CYTKCytokinetics Incorporated | 50.78 | -1.32% | $7.07B | vs AMRX |
| PTGXProtagonist Therapeutics Inc. | 121.40 | -2.11% | $7.92B | vs AMRX |
| CORTCorcept Therapeutics Incorporated | 63.62 | -2.09% | $6.96B | vs AMRX |
| SMMTSummit Therapeutics Inc. | 9.95 | -5.87% | $7.96B | vs AMRX |
| AXSMAxsome Therapeutics Inc. | 129.36 | -4.66% | $6.80B | vs AMRX |
Indexes, lists and sector
Amneal Pharmaceuticals stock FAQ
What is Amneal Pharmaceuticals's stock price today?
AMRX last traded at $21.12 as of Nov 20, 4:00 PM EST, down 1.26% on the day. Prices are delayed at least 15 minutes.
What is AMRX's P/E ratio?
AMRX trades at a trailing P/E ratio of 52.80 and a forward P/E of 17.13, compared with a median of 47.8 for its closest peers.
Who is Amneal Pharmaceuticals's CEO?
Mr. Chirag K. Patel is the chief executive officer of Amneal Pharmaceuticals Inc. Class A, which has about 8,700 employees.
What is the AMRX 52-week high?
The 52-week high for AMRX is $22.13 and the 52-week low is $11.71. The stock is currently 4.5% below its high.